{"url_path":"/sec/mbrx/8-k/2026-06-05/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-05","source_url":"https://www.sec.gov/Archives/edgar/data/1659617/0001437749-26-019660-index.html","accession_number":"0001437749-26-019660","cik":"0001659617","ticker":"MBRX","issuer_name":"Moleculin Biotech, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1659617/0001437749-26-019660-index.html","primary_entity_key":"0001659617","primary_entity_name":"Moleculin Biotech, Inc."},"word_count":127,"has_tables":true,"body_markdown":"**Item 7.01**\n\n**Regulation FD Disclosure**\n\n \n\nOn June 5, 2026, Moleculin Biotech, Inc. (the “Company”), issued a press release which announced results from an independent market landscape assessment evaluating Annamycin in relapsed/refractory acute myeloid Leukemia (R/R AML).\n\n \n\nA copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.\n\n \n\nThe information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (“Securities Act”), unless specifically identified therein as being incorporated by reference."}